SCHEMBL15935402

SCHEMBL15935402

Cc1ccn(-c2ccnc(N(C)C)n2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.56
RAB9A P51151 2/20 0.56
NPC1 O15118 1/20 0.56
ATM Q13315 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
DYRK1A Q13627 13/20 0.43
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
TDO2 P48775 1/20 0.34
HTT P42858 1/20 0.34
ADORA2A P29274 1/20 0.33
DYRK3 O43781 1/20 0.33
CLK1 P49759 1/20 0.33
CLK2 P49760 1/20 0.33
CLK3 P49761 1/20 0.33
JAK3 P52333 1/20 0.33
CDK5 Q00535 1/20 0.33
CDK5R1 Q15078 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15923593 0.82 DYRK1A (0.40) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL19100786 0.81 MAPT (0.58) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL15935396 0.81 MAPT (0.61) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL15935018 0.75 MAPT (0.54) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL15935017 0.74 MAPT (0.53) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL15935025 0.74 MAPT (0.53) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL197523 0.72 MAPT (1.00) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL11983495 0.70 RAB9A (0.52) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL24142366 0.70 PDE10A (0.42) DYRK1ADYRK3CLK1CLK2CLK3
SCHEMBL1586782 0.69 DYRK1A (0.42) DYRK1ADYRK3CLK1CLK2CLK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9708308-B2 Factor IXa inhibitors MERCK SHARP DOHME CORP. (US) 2017-07-18 US disclosed
US-20150322056-A1 Factor IXa Inhibitors MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-11-12 US disclosed
WO-2014120346-A1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322056-A1 Factor IXa Inhibitors F9, F12, F8 MAPT 4751/4885RAB9A 556/4885NPC1 1192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.